Adaptive trial design
11 important questions on Adaptive trial design
What are the disadvantages of a traditional trial to use a adaptive trial?
- Late recognition of efficacy
- Underpowered
- Inefficient use or resources = funding randomization
What can you adapt in an adaptive trial?
One or more aspects.
You can address these questions
• What is a safe dose? => dose
• Which treatment option is best? => treatments
• Which patients will benefit? => patients
• Does the treatment work?
What is the current/old used method to analyse the safe dose of medication?
When two or more patients experience side effects => trial is done.
- Higher grades + faster learning
- Never study anything twice
- 100% sure, 100% understanding
What is the difference between the 3+3 method and continual re-assessment method?
- At the start of the study you make a model to predict toxicities, at different dose levels.
- The study is in different parts/groups => when one group is done you make a new model and base the dosis on the new model for the new group.
- This minimizing the number of patients exposed to too-low or too-high doses
- So the data of all patient is used => compared to only of the three before in the 3+3 model.
To investigate which treatment option is the best. What can you use?
- Multiple treatment and multiple changes in the treatments that are available
- You can stop one treatment when it is not effective
CONS= You have to set early endpoints.
2. Response adaptive randomization
You change the ratio based on the responses of the patients. The probability of getting the less effective drug becomes smaller and smaller.
What are pro's and cons of the response adaptive randomization trial?
- You prevent more harm
- You are more effective when you have multiple treatments and only one control.
- more complicated to explain to the patient and doctor
- Statistically difficult
- It can not be blinded
- What to do with outliners.
What is a covariate-adjusted response adaptive trial?
Randomization probability aligned to the biomarkers of the patient.
- So you have a group of people, they are divided based on biomarkers.
- You randomize patients to different treatments; based on a biomarker. => (so there is an idea about which patients (with certain biomarkers) will benefit form which treatment).
What are population enrichment studies?
=> you continue adding patients that probably will benefit.
- so that you do not add patients that wont benefit
- what are the stopping rules?
What is the goal of group sequential trials?
- Stop a trial early if there is enough evidence that the treatment works (efficacy) or does not work (lack of benefit)
- Predefined stopping rules => set a goal like you want 33% difference between placebo and treatment => during the interim analysis you evaluate.
What are general limitations for adaptive trial designs?
- Not possible with small and quick studies
- Not possible for long term endpoints >6 months.
What are ethical considerations for a adaptive trial?
- Understanding of doctors
- Understanding of patients => informed consent
- How much funding do you need => you dont know this beforehand
- Do doctors want to participate?
The question on the page originate from the summary of the following study material:
- A unique study and practice tool
- Never study anything twice again
- Get the grades you hope for
- 100% sure, 100% understanding

















